Clinical trials
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma clinical trials
Below are recruiting relapsed or refractory b-cell non-hodgkin lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,759 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02582697RecruitingPhase 3
Faster vs standard chemotherapy for spreading germ cell tumors
This Phase 3 trial compares a faster chemotherapy approach versus the standard schedule for people with intermediate- or poor-risk metastatic germ cell tumors. The goal is to see which schedule works better and is safer enough to use as initial treatment.
New York, New YorkAges 11–50 - NCT02443831RecruitingPhase 1
CAR T-cell immunotherapy for high-risk childhood leukemia
This early-phase trial tests CAR T-cells made to attack leukemia cells with specific markers (CD19 and CD22). It may help people with difficult-to-treat, relapsed, or high-risk acute lymphoblastic leukemia (ALL), especially when standard treatments haven’t worked well.
LondonAges Up to 24 years - NCT02919644RecruitingPhase 2
Cancer vaccine made from your own cells after bowel cancer surgery
This trial tests whether a personalized vaccine—made from your own immune cells mixed with your own tumor material—can help prevent colorectal cancer from coming back after curative surgery. It may help your immune system recognize and fight any remaining cancer cells.
Meldola, FCAges 19 years+ - NCT07397975Recruiting
Using speech to predict relapse in psychosis
This study uses speech recordings from a smartphone app to see if changes in the way you talk can predict when someone might have a relapse of psychosis. It is for people who are currently stable or for healthy volunteers to compare.
KlecanyAges 18–65 - NCT07408063RecruitingPhase 2
Study of new drug for advanced head and neck cancer
This trial tests a new drug (GSK5764227) for head and neck cancer that has spread or come back. It looks at your tumor's biomarkers to understand why some people respond to treatment. You may need to have had certain prior treatments depending on which group you join.
Toronto, OntarioAges 18 years+ - NCT05952804RecruitingPhase 2
IVIG to help prevent infections after CAR-T treatment
This Phase 2 study tests whether IVIG (a blood product that helps fight infections) can lower infection risk after you receive CD19 CAR-T therapy. It’s meant to help protect you during the vulnerable period after CAR-T treatment.
Duarte, CaliforniaAges 18 years+ - NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75 - NCT07530094RecruitingPhase 2
Radiation and chemotherapy with immunotherapy for advanced esophageal cancer
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
Nanjing, JiangsuAges 18–75 - NCT07554898RecruitingPhase 2
Low-dose Radiation Plus Orelabrutinib for Early-stage MALT Lymphoma
This trial tests combining very low-dose radiation therapy with a targeted drug called orelabrutinib (a type of cancer-fighting protein inhibitor) as a first treatment for early-stage MALT lymphoma, a slow-growing blood cancer. The goal is to see if this combination can shrink or control the cancer with fewer side effects than standard chemotherapy.
Hangzhou, ZhejiangAges 18 years+ - NCT07555470RecruitingPhase 2
New drugs for follicular lymphoma: mosunetuzumab and zeprumetostat
This study tests two new drugs combined together to treat follicular lymphoma (a slow-growing blood cancer). The trial enrolls patients who have never been treated, those with limited disease who want active treatment, and those whose cancer came back or didn't respond to prior therapy.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07565532Recruiting
Small Cell Lung Cancer Treatment Study With Radiation
This study follows patients with small cell lung cancer who receive radiation therapy combined with other treatments. Researchers will track how well the treatment works and how patients respond over time to help improve future care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07604909RecruitingPhase 2
Serplulimab plus chemotherapy for early-relapsed colorectal cancer
This trial tests a new immunotherapy drug called serplulimab combined with standard chemotherapy or targeted therapy for colorectal cancer that has come back within a year after surgery. The goal is to see if adding this immune-boosting drug helps control the cancer better than chemotherapy alone.
ShanghaiAges 18 years+ - NCT07668557RecruitingPhase 1
CLL1-CD33 CAR-T cells for relapsed or refractory acute myeloid leukemia
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
Nanchang, JiangxiAges 18–70 - NCT06223074Enrolling by invitationPhase 2
Nasal Steroid Spray for MS Relapses
This study tests a nasal spray form of the steroid methylprednisolone for treating MS relapses. The goal is to see if this new way of taking the medicine works as well or better than standard treatments.
Mexico CityAges 18–65 - NCT05905328RecruitingPhase 1/Phase 2
New drug to prevent and treat side effects of CAR T-cell therapy
This study tests an experimental drug, CTO1681, that may help prevent or treat cytokine release syndrome (CRS) — a common side effect of CAR T-cell therapy. It could make the recovery period safer and more comfortable.
Orange, CaliforniaAges 18 years+ - NCT06676059Recruiting
Substance use monitoring study with a smartphone app
This study uses a smartphone app and daily surveys to track alcohol or drug use. It aims to create a database for future research on addiction patterns and recovery.
Baltimore, MarylandAges 18–120 - NCT06904066RecruitingPhase 1
Custom T cells for blood cancers with specific mutations
This trial tests a personalized treatment where your immune cells are collected, modified to recognize unique cancer markers (neoantigens) from TP53 or RAS mutations, and returned to fight blood cancers like AML, MDS, or multiple myeloma.
Bethesda, MarylandAges 18–120 - NCT06648889RecruitingPhase 2
Isatuximab for relapsed or hard-to-treat T-cell leukemia
This trial tests a drug called isatuximab for people with a type of leukemia (T-cell acute lymphoblastic leukemia) that has come back after treatment or that did not go away. Isatuximab targets a protein on the leukemia cells, which might help the immune system fight the disease.
AugsburgAges 18 years+ - NCT07439211RecruitingPhase 1
Testing a new drug combo for acute myeloid leukemia
This trial tests a new drug, eganelisib, combined with azacitidine and venetoclax for patients with acute myeloid leukemia (AML). It's for people whose AML has come back or hasn't responded to treatment, or for those with a high-risk type who haven't been treated yet.
Boston, MassachusettsAges 18–90 - NCT06701812RecruitingPhase 2
Digoxin for relapsed non-WNT non-SHH medulloblastoma
This trial tests whether the drug digoxin can help treat medulloblastoma that has come back after standard treatments like chemotherapy and radiation. Digoxin is a heart medicine being studied for its anticancer effects against a specific type of medulloblastoma.
Birmingham, AlabamaAges 1–30 - NCT04322318RecruitingPhase 2
Study of combination chemotherapy for Wilms tumor in children
This Phase 2 trial tests combination chemotherapy for children with certain types of Wilms tumor—either newly diagnosed diffuse anaplastic Wilms tumor or favorable Wilms tumor that has come back. The goal is to see how well the treatment controls the tumor and is tolerable for children.
Birmingham, AlabamaAges Up to 30 years - NCT05702645Recruiting
Down syndrome long-term study after leukemia treatment
This study follows children and young adults with Down syndrome who have survived acute leukemia (ALL or AML) to learn about their longer-term health after treatment ends. It may help families and doctors understand what health problems to watch for and how to provide better follow-up care.
Birmingham, AlabamaAges 6–39 - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Birmingham, AlabamaAges Up to 22 years - NCT04838041RecruitingPhase 2
Testing stopping treatment after asciminib for CML relapse
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
Detroit, MichiganAges 18 years+
Hear when a new Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell non-hodgkin lymphoma?
- Yes. Clin2 currently lists 1,759 recruiting relapsed or refractory b-cell non-hodgkin lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell non-hodgkin lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.